Rating Change
HC Wainwright & Co. analysts downgraded Heron Therapeutics, Inc. (NASDAQ:HRTX) from Buy to Neutral on August 11, 2026.
downgradeNASDAQ:HRTX
Heron Therapeutics, Inc. (HRTX) Downgraded to Neutral by HC Wainwright & Co.
HC Wainwright & Co. analysts downgraded Heron Therapeutics, Inc.
At publication ·
What changed
Heron Therapeutics, Inc. (NASDAQ:HRTX) · downgrade
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Neutral
- Price at event
- $0.33
- Market capitalization
- $214.8M
At a glance
Key takeaways
- HC Wainwright & Co. downgraded Heron Therapeutics (HRTX) from Buy to Neutral on August 11, 2026, marking a shift in analyst sentiment on the stock.
Market Context
Heron Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $0.33 with a market capitalization of $214.8M.
Analyst downgrades can weigh on a stock in the short term as institutional investors who follow HC Wainwright & Co.'s research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Heron Therapeutics, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Jun 03, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 03, 2026 | Needham | Hold | N/A |
| Jan 09, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 08, 2025 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View HRTX Stock Page
Frequently Asked Questions
What does the Neutral rating mean for HRTX?
A rating of Neutral from HC Wainwright & Co. reflects the analyst's outlook on Heron Therapeutics, Inc. (NASDAQ:HRTX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the HRTX forecast page.